findmyKOL
Clinical trialNCT06795009RecruitingPhase 1Interventional

Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

SponsorWashington University School of MedicineEnrollment36Endometrial CancerUterine Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine the recommended Phase 2 dose of zanzalintinib when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer. Other objectives include overall safety and tolerability as well as rates of response.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of California, San Francisco

    San Francisco, California, United States

    Katherine Fuh, M.D., Ph.D.
    Not, yet, recruiting
  • Washington University School of Medicine

    St Louis, Missouri, United States

    Andrea R Hagemann, M.D.Carolyn McCourt, M.D.David G Mutch, M.D.Dineo Khabele, M.D.Esther Lu, Ph.D.Ian Hagemann, M.D.L. Stewart Massad, M.D.Lindsay Kuroki, M.D.Maggie Mullen, M.D.Matthew A Powell, M.D.Premal Thaker, M.D.Veronica Davé, Ph.D.
    Recruiting
  • University of New Mexico

    Albuquerque, New Mexico, United States

    Carolyn Muller, M.D.
    Not, yet, recruiting
  • University of Oklahoma

    Oklahoma City, Oklahoma, United States

    Kathleen Moore, M.D.
    Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PaclitaxelZanzalintinib
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
17 Oct 2025
Primary completion
30 Nov 2029
Completion
30 Apr 2035
Last update posted
11 Dec 2025
Registered enrollment
36
Registry id
NCT06795009
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.